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Abstract
MicroRNAs are key regulators of gene expression and have been shown to have altered expression in a variety of cancer
types, including epithelial ovarian cancer. MiRNA function is most often achieved through binding to the 39-untranslated
region of the target protein coding gene. Mutation screening using massively-parallel sequencing of 712 miRNA genes in 86
ovarian cancer cases identified only 5 mutated miRNA genes, each in a different case. One mutation was located in the
mature miRNA, and three mutations were predicted to alter the secondary structure of the miRNA transcript. Screening of
the 39-untranslated region of 18 candidate cancer genes identified one mutation in each of AKT2, EGFR, ERRB2 and CTNNB1.
The functional effect of these mutations is unclear, as expression data available for AKT2 and EGFR showed no increase in
gene transcript. Mutations in miRNA genes and 39-untranslated regions are thus uncommon in ovarian cancer.
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Introduction
MicroRNAs (miRNAs), a class of small non-coding RNA
molecules, have important regulatory roles in diverse cellular
pathways including proliferation, differentiation, senescence and
metabolism [1]. This regulation is achieved through semi-
complementary base paring with the 39-untranslated region (39-
UTR) of the target messenger RNA (mRNA) [1–3], as well as the
59-untranslated region or coding regions of mRNAs, which are
subsequently degraded or post-transcriptionally silenced [4–6].
Accumulating evidence now demonstrates that miRNA expression
is aberrant in cancer [7], leading to the hypothesis that alterations
in miRNA pathways may be an important step in the initiation
and progression to malignancy. Consistent with this hypothesis is
the observation that miRNA genes are frequently localised in
genomic regions commonly altered in cancer, including minimal
regions of deletion, loss of heterozygosity and amplification as well
as fragile sites [8–10]. Mutation is an alternative mechanism for
miRNA deregulation in the cancer setting, whereby mutation may
alter miRNA transcription, processing or miRNA-mRNA inter-
actions. This mechanism was first described by Calin et al. [8], who
identified a germline variation in hsa-miR-16-1 that was linked with
susceptibility to chronic lymphocytic leukaemia. Since then,
germline polymorphisms in miRNA genes have been associated
with predisposition to other cancer types [11]. Despite the
hypothesis that miRNAs may function as conventional oncogenes
or tumor suppressors, several studies have suggested that somatic
mutation within miRNAs are a rare occurrence and those that
have been reported show little effect on miRNA activity [10,12–
14]. However, the majority of these studies have favoured a
candidate gene approach and to date, un-biased assessment of the
occurrence of somatic alterations in miRNA genes in any cancer
type is lacking.
Analogous to mutations occurring within miRNA seed regions,
mutations occurring within the target mRNA sequence may alter
binding and subsequent miRNA-dependent regulation of gene
expression. While germline alterations at miRNA binding sites in
39-UTRs may contribute to cancer susceptibility [11,15–17],
reports of somatic mutations occurring in a similar context is
limited to a single case report [13] and has yet be to investigated in
large tumor cohorts. If somatic mutations do occur at miRNA
binding sites, it would constitute a previously unexplored genetic
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mRNA.
Aberrant miRNA activity is frequently associated with the
pathogenesis and progression of epithelial ovarian cancer, the most
common form of ovarian malignancy. MiRNA profiling studies
consistently observe global silencing of miRNA expression in
ovarian tumors, which is contributed to in part by genomic loss
and epigenetic alterations [10,18–22]. Similarly, expression of
many known and putative cancer genes is dysregulated in ovarian
cancer, for example BRCA2, for which only a proportion of the
observed loss of expression can be attributed to mutation, and
promoter methylation is not observed [23]. Previously, we have
demonstrated that the frequency of somatic mutations in 10
cancer-implicated miRNAs is low in ovarian tumors [24]. In the
present study, we extend this analysis by comprehensively
characterising somatic mutations in 712 miRNA genes using
massively parallel targeted re-sequencing. In addition, we screened
the 39-UTRs of 18 candidate cancer genes with the aim of
identifying somatic mutations that alter predicted miRNA binding
sites. Although these genes are frequently implicated in the
tumorigenic process, coding mutations, methylation or copy
number alterations only account for a subset of the expression
differences seen in ovarian tumors.
Results and Discussion
Somatic mutations targeting microRNA genes are
infrequent events in ovarian tumors
To investigate whether mutations in miRNA genes contribute to
altered miRNA activity in ovarian cancer, 86 primary epithelial
ovarian tumors were assessed for somatic mutations in genomic
regions corresponding to precursor or mature miRNA sequences.
Clinical characteristics of these cases are summarised in Table S1.
Targeted next generation sequencing was used to assess 712
miRNA genes annotated in the Sanger miRNA database (version
13.0, March 2009). Following data alignment, 95% of targeted
bases within the 712 miRNA genes had a minimum 10-fold
sequence coverage, with a corresponding mean coverage of 92-
fold. Filtering to remove germline variants detected in matched
normal lymphocyte DNA and validation by conventional
sequencing identified somatic mutations in 5 miRNA genes: hsa-
miR-10a, hsa-miR-622, hsa-miR-767-5p, hsa-miR-888 and hsa-miR-
1280 (Figure 1). Overall, somatic mutations were detected in 6%
(5/86) of tumors and in less than 1% (5/712) of miRNA genes
analysed, with no miRNA genes recurrently targeted by mutation.
Consistent with previous reports, mutations within mature
miRNAs were uncommon; only one mutation was located within
the mature region of hsa-miR-767-5p (but external to the seed
region), whilst the remaining four occurred within the precursor
hairpin. This data is in agreement with previous smaller scale
studies suggesting that somatic mutations in miRNA genes are an
infrequent event in tumor samples [8,12,14,24,25].
MiRNA biogenesis is a multistep process initiated by RNA
polymerase II-mediated transcription, followed by RNAse III-
dependent trimming into a hairpin intermediate and subsequent
cleavage into a functional mature miRNA [1,26]. This process is
dependent on sequence motifs and RNA secondary structure
elements within the primary and precursor miRNA molecules
[26]. As such, mutations arising in precursor regions may alter
RNA secondary structure and thereby block processing into
mature miRNA. To determine if RNA structural changes may
result from the somatic miRNA mutations identified, we used the
RNAfold program [27] to predict the most stable secondary
structure for both the wild-type and mutant sequences. Confor-
mational changes were predicted for mutant hsa-miR-622, hsa-miR-
767-5p and hsa-miR-1280 (Figure S1). However, conformational
changes predicted in silico rarely equate to a physiological effect
[12] and the functional implication of mutations identified here
requires further investigation with in vitro assays.
In contrast to the frequent observation of tumor-specific
variations contributing to the activation or repression of protein
coding genes in cancer, these findings demonstrate that somatic
mutations in miRNA genes are an infrequent event during ovarian
pathogenesis and add to accumulating evidence from a range of
tumor types suggesting that miRNAs are rarely dysregulated by
this mechanism. Given the large number of mRNA targets
predicted for a single miRNA and the diverse roles of those
predicted target genes, any somatic mutation in a miRNA gene
(and particularly those occurring within the seed sequence) are
likely to impact many biological pathways [2,3], some of which
may be involved in maintaining cell homeostasis. Consequently,
even if a somatically mutated miRNA gene altered mRNA
expression to positively affect tumor survival, it is likely that there
would be a larger number of gene expression changes which would
not be conducive to tumor cell survival. Conversely, in certain
situations, mRNA transcriptional repression may result from the
action of multiple miRNAs [28] and as such, the altered activity of
a single miRNA may be insufficient to result in a biological effect.
Finally, it is becoming increasingly recognised that miRNA
alterations observed in cancer tissues may occur secondary to
defects in components of the miRNA processing machinery,
including transcription factors and chromatin remodelling genes
regulating miRNA transcription, as well as components of miRNA
post-transcriptional regulation [29,30]. In ovarian tumors, DIC-
ER1 and EIF2C2 (Argonaute2) DNA copy number gains have
been observed in 24.5% and 51.5% of tumors respectively [9] and
median overall survival is reduced among women whose tumors
have lower DICER1 and DROSHA mRNA expression [31].
Further investigation is needed establish the importance of
alterations to these and other components of the miRNA
biogenesis pathway in the pathogenesis of ovarian cancer.
Somatic mutations targeting 39-untranslated regions are
infrequent events in ovarian tumors
To investigate the possibility that somatic mutations occurring
within the 39-UTRs of cancer genes alter an existing miRNA
binding site, and thus signify a novel mechanism for aberrant
mRNA gene expression in cancer, we sequenced the 39-UTRs of
11 oncogenes (AKT2, BRAF, CCNE1, CTNNB1, EGFR, ERBB2,
FGF1, KRAS, MYC, PIK3CA and RAB25) by targeted re-sequencing
in the 86 ovarian tumors. In the case of an oncogene, abrogation
of a miRNA binding site may permit unregulated oncogene
expression. In addition, the 39-UTRs of 7 tumor suppressor genes
(TSGs) (BRCA1, BRCA2, CDKN2A, PTEN, RB1, SPARC and TP53)
were also sequenced to assess the prevalence of somatic mutations
that would generate a de novo miRNA binding site and result in
TSG down-regulation. These genes are recognized by the Cancer
Gene Census to be causally implicated in ovarian tumour
development either by somatic mutation, gene amplification or
deletion [32]. FGF1, RAB25 and SPARC were chosen based on
their demonstrated functional role in ovarian cancer [33–37]. 39-
UTRs were sequenced to 108-fold mean coverage and greater
than 99% of the targeted bases within these regions were covered
by 10 or more sequence reads. Tumor-specific mutations were
infrequently identified in the 39-UTRs of ovarian samples: 4/86
tumor samples were each identified with a mutation in one of four
different oncogenes (AKT2, CTNNB1, EGFR and ERBB2) (Table 1),
with no mutations detected in the 7 TSGs investigated. In silico
miRNA and 39-UTR Mutations Rare in Ovarian Cancer
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AKT2, CTNNB1 and ERBB2 may occur within the region of a
predicted miRNA binding site, with two mutations, the
c.*538T.A( CTNNB1) and c.*460G.C( ERBB2) substitutions,
predicted to occur within the seed sequence of hsa-miR-630 and
hsa-miR-640 binding respectively. RNA expression profiling was
available for samples with mutations in AKT2 and EGFR and
demonstrated that the transcript levels of these genes was not
altered in samples with somatic 39-UTR mutations relative to
other tumor samples of the same ovarian subtype (Figure S2).
Although it is recognised that miRNAs can also impart
transcriptional repression through action on the 59-UTR of an
mRNA target, this study provides preliminary evidence that
somatic mutations altering miRNA binding sites within the 39-
UTR of common cancer genes are infrequent in epithelial ovarian
tumors. Effective translational silencing may require synergistic
action of miRNAs at multiple sites across a UTR, either by a single
family of microRNAs or by a combination of unrelated
microRNAs, and thus the single somatic mutations identified here
are likely insufficient to silence the respective transcript [28,38].
The somatic mutation prevalence in 39-UTR regions of candidate
cancer genes sequenced was 1.43 mutations per Mb. By
comparison, the mutation prevalence in protein coding regions
of known cancer genes in this tumor cohort is 570.57, 183.60 and
32.63 mutations per Mb for TP53, KRAS and PIK3CA respectively,
while the estimated mutation prevalence in the coding exome is
2.4 mutations per Mb in ovarian tumors [23]. Thus, it is likely that
the low rate of mutation in 39UTRs compared to exons indicates
that the majority of mutations in 39-regulatory regions identified
here occur as bystander events in tumor cell development.
In summary, somatic mutations in miRNA genes were
infrequently observed in ovarian tumors and thus are unlikely to
account for altered miRNA activity observed in this tumor type. In
addition, we provide preliminary evidence that selection for
somatic mutations within the 39-UTRs of candidate cancer genes,
which would be hypothesised to interfere with miRNA dependent
gene regulation, is unlikely to represent a common mechanism for
altered mRNA expression in ovarian tumors.
Materials and Methods
Ethics statement
Accrual and use of patient material for this study was approved
by the following Human Research Ethics Committees: South-
ampton Hospital Human Research Ethics Committee, Peter
MacCallum Cancer Centre Human Research Ethics Committee,
Queensland Institute of Medical Research Human Research
Ethics Committee, University of Melbourne Human Research
Ethics Committee, Westmead Hospital Human Research Ethics
Committee. All individuals gave written informed consent for the
use of their tissue in research. This project was approved by the
Peter MacCallum Cancer Centre Human Research Ethics
Committee (Approval # 09/29).
Figure 1. Somatic mutations identified in microRNA genes. Tumor specific mutations are marked as black bars relative to the mature
microRNA (white box) and precursor microRNA (grey box) sequences. The positions of mutations are reported with respect to the following precursor
microRNA transcripts: hsa-miR-10a NR_029608.1; hsa-miR-622 NR_030754.1; hsa-miR-767-5p NR_030409.1; hsa-miR-888 NR_030592.1; hsa-miR-1280
NR_031703.1.
doi:10.1371/journal.pone.0035805.g001
Table 1. Somatic mutations identified in 39-untranslated regions of candidate mRNAs.
Gene Nucleotide change
1
MicroRNA binding affected by
mutation Predictive algorithm Sample ID
AKT2 c.*892C.T hsa-miR-429 DIANA-microT [47,48] P1768
CTNNB1 c.*538T.A hsa-miR-640
2 miRanda [49] P0511
hsa-miR-10a miRanda
hsa-miR-587 miRanda
EGFR c.*101C.G - - IC151
ERBB2 c.*460G.C hsa-miR-495 miRanda P5514
hsa-miR-630
2 microCOSM Targets [40]
1Nucleotide changes are described relative to the following sequences: AKT2 NM_001626.3; CTNNB1 NM_001904.3; EGFR NM_005228.3; ERBB2 NM_004448.2.
2Indicates that the somatic mutation occurs within the microRNA-mRNA interaction at the seed region.
doi:10.1371/journal.pone.0035805.t001
miRNA and 39-UTR Mutations Rare in Ovarian Cancer
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86 primary epithelial ovarian tumor tissue samples were
obtained through the Peter MacCallum Cancer Centre Tissue
Bank, Australia Ovarian Cancer Study or from patients presenting
to hospitals in the south of England [39]. All tumor DNA samples
were microdissected to ensure greater than 80% epithelial cell
component. This tumor cohort comprised a mixture of serous
(n=45), endometrioid (n=28), mucinous (n=7) and clear cell
(n=6) subtypes. Matching peripheral blood samples were also
collected from all patients at time of tumor collection and used as a
source of germline DNA.
Candidate region identification for targeted next-
generation sequencing
The 39-UTRs of 18 protein coding genes were selected for
somatic mutation screening. Genome co-ordinates for selected 39-
UTRs were identified based on those annotated in the Ensembl
database (release 54) for the following transcripts: AKT2
(ENST00000392038), BRAF (ENST00000288602), CCNE1
(ENST00000262643), CTNNB1 (ENST00000349496), EGFR
(ENST00000275493 and ENST00000344576), ERBB2
(ENST00000269571), FGF1 (ENST00000359370), KRAS
(ENST00000256078), MYC (ENST00000259523 and
ENST00000377970), PIK3CA (ENST00000263967), RAB25
(ENST00000361084), BRCA1 (ENST00000309486), BRCA2
(ENST00000380152), CDKN2A (ENST00000304494), PTEN
(ENST00000371953), RB1 (ENST00000267163), SPARC
(ENST00000231061) and TP53 (ENST00000269305). The geno-
mic co-ordinates for human precursor miRNAs were obtained
from the Sanger Institute miRBase (release 13.0, March 2009)
[40,41], including 548 individual miRNA genes as well as 164
miRNAs within 62 miRNA clusters. All coding exons of TP53,
KRAS and PIK3CA were included for sequence analysis.
Library preparation and target enrichment
200 ng of tumor or matched normal lymphocyte DNA was
randomly fragmented to approximately 200 bp (Covaris, Woburn,
MA) and end repair and A-tailing performed according to the
Illumina genomic DNA library preparation protocol (Illumina,
San Diego, CA). Following this, DNA was ligated with one of 7
custom multiplexing adapters compatible with Illumina single end
sequencing. Indexed DNA samples were pooled equally prior to
PCR enrichment. All reagents used during library preparation
were obtained from New England Biolabs (NEB, Ipswich, MA). A
boutique exon capture (SureSelect, Agilent Technologies, Santa
Clara, CA) was used to specifically enrich for selected 39-UTRs,
miRNAs and coding exons of cancer genes from genomic DNA
libraries prior to next generation sequencing. Capture probes were
designed using default parameters by submitting genomic co-
ordinates to eArray (Agilent Technologies, Santa Clara, CA).
Solution hybridization, washing, elution and amplification were
performed according to the recommended protocol.
Somatic mutation analysis by Illumina GAIIx sequencing
and capillary electrophoresis
Target enriched DNA libraries were sequenced on an Illumina
GAIIx, generating 75 bp single end sequence reads. Image
analysis and base calling was performed using the Genome
Analyser Pipeline v1.6. Sequence reads were aligned to the human
reference genome (GRCh37/hg19 assembly) using BWA and
remaining unmapped reads were aligned with Novoalign software
[42]. This was followed by local realignment with GATK [43].
Point mutations and insertions/deletions (indels) were identified
using GATK and Dindel [44] respectively and annotated with
information from Ensembl release 56. Only mutations within
miRNA transcripts annotated in miRBase were considered for
further analysis.
Point mutations and indels were identified as somatic alterations
only when (i) the variant was not called in the matched normal
sample or identified as a germline alteration in another tumor/
normal pair (ii) the variant was not seen in .2% of reads in the
matched normal sample following manual inspection of sequence
reads using the Integrated Genomics Viewer [45] (iii) the variant
was identified in at least four unique sequence reads with at least
two mapping in the forward and two mapping in the reverse
orientation.
All mutations which met the above criteria were subjected to
validation by conventional PCR amplification and bidirectional
capillary electrophoresis on the ABI3130 Genetic Analyser using
BigDye Terminator v3.1 sequencing chemistry (Applied Biosys-
tems, Foster City, CA).
Identification of miRNA-binding sites
The TargetScan (release 5.2) [46], microCOSM Targets
(version 5) [40], DIANA-MicroT (version 3.0) [47,48] and
miRanda (release August 2010) [49] predictive algorithms were
used to determine whether the somatic mutations detected in
mRNA 39UTRs occurred within miRNA binding sites. A mirSVR
score threshold of less than 20.1 and minimum folding energy
score threshold of less than or equal to 216 kcal/mol were used
for the miRanda algorithm. Default parameters were used for all
other algorithms.
Supporting Information>
Figure S1 Predicted secondary structure changes as a
result of somatic mutations in miRNA transcripts.
Mature sequences are shadowed and the mutated base indicated
by the arrowhead in (a) hsa-miR-622,( b) hsa-miR-1280 and (c) hsa-
miR-767-5p. The precursor miRNA sequence plus 50 bp flanking
the precursor at the 59 and 39 ends was used to predict the
secondary structure with the lowest free energy by the RNAfold
program [29] using default parameters.
(PDF)
Figure S2 AKT2 and EGFR mRNA expression is not
altered in the presence of 39-untranslated region somatic
mutations relative to other ovarian samples of the same
subtype.( a) AKT2 expression in endometrioid tumors, including
sample P1768 with an AKT2 c.*892C.T somatic mutation
(indicated in red). mRNA expression profiling data was obtained
from Tothill et al. [50]. AKT2 expression probe sets 225471_s_at
and 226156_at are shown. (b) EGFR expression in endometrioid
tumors, including sample IC151 with an EGFR c.*101C.G
somatic mutation (indicated in red). mRNA expression profiling
data was obtained from Ramakrishna et al. [51]. Error bars are
representative of mean 6 SD.
(PDF)
Table S1 Clinical characteristics of ovarian tumors
sequenced for somatic mutations in microRNA genes
and candidate 39-untranslated regions.
(XLS)
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